Neuroleptic malignant syndrome with promethazine [1]

Australian and New Zealand Journal of Psychiatry

Volumn 39, Issue 4, 2005, Pages 310-

  Mendhekar, Dattatrya Namdeorao ^a   Andrade, Chit Ranjan ^b  

^a G B PANT HOSPITAL   (India)

^b NIMHNAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CLOZAPINE; OLANZAPINE; PROMETHAZINE; RISPERIDONE; TRIFLUOPERAZINE;

ADULT; ANAMNESIS; CASE REPORT; CATATONIC SCHIZOPHRENIA; CLINICAL FEATURE; CONFUSION; DEHYDRATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAPHORESIS; DISEASE DURATION; FEMALE; FEVER; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INCONTINENCE; LETTER; LIVER DYSFUNCTION; MENTAL DISEASE; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; VOMITING;

EID: 18044374084     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1080/j.1440-1614.2005.01568.x     Document Type: Letter

References (5)

1. Chan-Tack KM. Neuroleptic malignant syndrome due to promethazine. South Medical Journal 1999; 92:1017-1018.
2. Duggal HS. Neuroleptic malignant syndrome precipitated by promethazine and lorazepam. Australian New Zealand Journal of Psychiatry 2001; 35:250-251.
3. Tenenbein M. The neuroleptic malignant syndrome: occurance in a 15-year-old boy and recovery with bromocriptine therapy. Pediatric Neuroscinces 1986; 12:161-164.
4. Fink M, Taylor MA. Catatonia. A clinician's guide to diagnosis and treatment. Cambridge, UK: Cambridge University Press, 2003.
5. White DAC. Catatonia and neuroleptic malignant syndrome: a single entity? British Journal of Psychiatry 1992; 161:558-560.